Cyclosporine (CSA) as Add-On Therapy in Omalizumab (OMA)–Refractory Chronic Spontaneous Urticaria: A Retrospective Review from Hamad General Hospital, Qatar

World Allergy Organization Journal 2026 Open access

Read full text
Authors: Sherin Rahim Thalappil, Sara Saeed Ibrahim Mohamed, Maryam Ali Al‐Nesf, Ramzy Mohammed Ali
DOI: 10.1016/j.waojou.2026.101267
Cited by: 0

Abstract

A subset of patients with chronic spontaneous urticaria (CSU) remain symptomatic despite high-dose antihistamines and omalizumab. Cyclosporine (CSA) is recommended as an add-on immunomodulator in refractory disease, yet real-world data from the Middle East are limited. This study evaluated the effectiveness and safety of CSA in OMA-refractory CSU in a tertiary center.

Fields of Study & Subjects

Urticaria and Related Conditions Mast cells and histamine Eosinophilic Disorders and Syndromes

Publication details

Journal / source
World Allergy Organization Journal
Volume
19
Issue
2
Pages
101267–101267
Publication date
1 February 2026
Language
EN